Precision p53 activation for cancer patients
We are making a highly specialized investigational drug candidate available to a limited number of solid-tumor patients through tightly curated, ethically aligned access programs.
Investigational product. Not FDA approved. Information here is educational and not medical advice.
What we’re exploring
- Re-activation of wild-type p53 signaling via dual inhibition of MDM2/MDMX.
- Small, signal-seeking studies and ethically compliant individual access pathways.
- Initial focus on p53 wild-type tumors; final eligibility to be determined with clinicians.
Mission
Our mission is to advance overlooked, potentially effective cancer therapies through disciplined, patient-focused development.
We will not collect protected health information (PHI) on this site. Submissions are interest-only; a clinician will determine eligibility.
Who might be a fit
- Adults with solid tumor cancers whose tumor characteristics are a match.
- Willing to consider clinician-supervised, self-funded access pathways.
- Open to sharing outcomes data if treated.
- Oncologists interested in SPINDs/expanded access or investigator-initiated research.
- Sites with capabilities for peptide administration and PK/biomarker sampling.
- Diagnostics groups for TP53 status confirmation.
- Funding partners aligned with ethical, patient-centric frameworks.
Final inclusion/exclusion criteria will be defined by treating clinicians and applicable regulations.
Join the interest list
This form does not collect PHI. Please do not share medical records. We’ll reach out with next steps if/when access becomes available.